News | February 27, 2022
Daewoong completes combination therapy of antidiabetic drug Enavogliflozin
Confirmed positive phase 3 topline results in addition to Enavogliflozin monotherapy and Metformin combination therapy
Confirmed positive phase 3 topline results in addition to Enavogliflozin monotherapy and Metformin combination therapy
N Yuvraj, Joint Secretary, Dept of Pharmaceuticals, Satish Reddy, Chairman, Dr Reddy’s Laboratories; Kiran Mazumdar Shaw, Executive Chairperson, Biocon Group; Sanjiv Navangul, MD & CEO, Bharat Serums and Vaccines and Shravil Patel, MD, Zydus Lifesciences discuss the way forward for the India pharma industry
The dedicated HPB and liver transplant centre will be headed by Dr. Vivek Vij, Chairman -Advanced Surgical GI, HPB & Liver Transplant and his team of experts
The COVID-19 pandemic has triggered the rapid growth of the biotherapeutics market
To be marketed by Strides Pharma Inc. in the US market
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines
AROC3-1001 is a phase 1/2, placebo controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-C3
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Canada
AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
